This is a StreetInsider.com Premium Only Page

(EVFM) – StreetInsider.com Reports

Apr 18, 2024 08:37 AM Evofem Biosciences (EVFM) Strengthens Phexxi Intellectual Property

Mar 27, 2024 08:37 AM Evofem Biosciences (EVFM) Reports FY23 Net Product Sales of Phexxi of $18.2M

Feb 1, 2024 08:02 AM Evofem Biosciences (EVFM) Reports Prelim FY23 Results

Dec 12, 2023 04:26 PM Laidlaw Downgrades Evofem Biosciences Inc (EVFM) to Hold

Dec 12, 2023 08:30 AM Aditxt, Inc (ADTX) to Acquire Evofem Biosciences (EVFM) for $100M

Oct 24, 2023 07:37 AM Evofem Biosciences (EVFMD) Reports Prelim Q4 Phexxi Sales of $5M-$5.2M

Sep 27, 2023 08:47 AM Evofem Biosciences (EVFM) Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi Until Evofem's Phexxi Patents Expire

Aug 22, 2023 04:01 PM Evofem Biosciences (EVFM) Seeks to List on a National Stock Exchange

May 17, 2023 04:51 PM Evofem Biosciences (EVFM) Announces 1:125 Reverse Stock Split

Apr 14, 2023 09:01 AM Evofem Biosciences (EVFM) Appoints Ivy Zhang as CFO

Apr 12, 2023 08:48 AM Evofem Biosciences (EVFM) Announces Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required

Mar 21, 2023 06:06 AM Evofem Biosciences (EVFM) Announces 39% Reduction in Payroll Expenses

Feb 28, 2023 08:48 AM Evofem Biosciences' (EVFM) Phexxi Contraceptive Gel Added to SimpleHealth Product Offering

Feb 27, 2023 07:48 AM Evofem Biosciences (EVFM) Announces FDA Orange Book Listing of Two Additional US Patents for Phexxi

Feb 23, 2023 08:34 AM Evofem Biosciences (EVFM) to Explore Strategic Alternatives

Jan 10, 2023 08:36 AM Evofem's (EVFM) Phexxi Added to Costco's Member Prescription Program

Jan 9, 2023 08:55 AM Evofem Biosciences (EVFM) Announces New Coverage for Phexxi

Oct 12, 2022 01:27 PM Stifel Downgrades Evofem Biosciences Inc (EVFM) to Hold

Oct 12, 2022 04:21 AM Evofem Biosciences (EVFM) Reports Phase 3 EVOGUARD Trial of EVO100 Did Not Achieve Endpoints

Sep 23, 2022 09:00 AM Evofem Biosciences (EVFM) Announces Issuance of U.S. Patent Covering Phexxi Composition of Matter

Sep 9, 2022 02:47 AM Evofem Biosciences Inc (EVFM) PT Lowered to $0.55 at Morgan Stanley

Jul 12, 2022 08:46 AM Evofem Biosciences (EVFM) Announces Publication of Phexxi's Mechanism of Action

Jun 30, 2022 11:23 AM Evofem Biosciences (EVFM) Climbs 15%

Jun 30, 2022 08:47 AM Evofem Biosciences (EVFM) Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO

Jun 28, 2022 10:19 AM Evofem Biosciences (EVFM) Receives Notice of Allowance for its US Patent - Patent Grants

Jun 28, 2022 06:49 AM Evofem Biosciences (EVFM) Enters Agreement with One of the Largest Pharmacy Benefit Managers in US for Access to Phexxi

Jun 27, 2022 12:13 PM Evofem Biosciences (EVFM) Climbs 175%

Jun 16, 2022 08:48 AM Evofem Biosciences (EVFM) Announces Phexxi Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data

Jun 2, 2022 08:46 AM Evofem Biosciences (EVFM) Announces FDA Extended Phexxi Shelf Life to Four Years

Jun 2, 2022 06:17 AM UPDATE: Laidlaw Starts Evofem Biosciences Inc (EVFM) at Buy, 'A Novel Niche Contraceptive with Sales Likely to Take off in 2022 and Beyond'

May 25, 2022 06:14 AM Evofem Biosciences Inc (EVFM) PT Lowered to $2 at Piper Sandler

May 20, 2022 09:14 AM Evofem Biosciences (EVFM) Prices Approximately $26.6 Million Public Offering of Common Stock, Warrants

May 20, 2022 05:52 AM Evofem Biosciences (EVFM) Announces Proposed Stock Offering, Size not Disclosed

May 11, 2022 03:10 AM Evofem Biosciences Inc (EVFM) PT Lowered to $2 at Morgan Stanley

May 5, 2022 09:01 AM Evofem Biosciences (EVFM) Announces 1-for-15 Reverse Stock Split

May 2, 2022 07:03 AM ObsEva SA (OBSV) Appoints Brandi Howard as Chief Clinical Officer

Apr 27, 2022 08:48 AM Evofem Biosciences (EVFM) Enters Agreement with VitaCare Prescription Services to Expand Support of Phexxi

Apr 19, 2022 06:53 AM Evofem Biosciences (EVFM) Announces Publication of Sexual Satisfaction Data Involving Phexxi from Evofem's Phase 3 AMPOWER Clinical Trial

Apr 12, 2022 03:49 AM Evofem Biosciences Inc (EVFM) PT Raised to $0.57 at Morgan Stanley

Apr 7, 2022 06:53 AM Evofem Biosciences (EVFM) Announces Nasdaq Accepts Plan to Regain Listing Compliance

Mar 4, 2022 02:23 AM Evofem Biosciences Inc (EVFM) PT Raised to $0.53 at Morgan Stanley

Feb 9, 2022 09:01 AM Evofem Biosciences (EVFM) Announces FDA Awards QIDP Designation for Prevention of Chlamydia

Jan 14, 2022 08:11 AM Evofem Biosciences Inc (EVFM) PT Raised to $3 at Stifel

Jan 12, 2022 07:32 AM Evofem Biosciences (EVFM) Announces Phexxi Access to Expand under New Government Guidance Stating Insurers Must Cover FDA-approved Contraceptives with No Out-of-Pocket Costs to Women

Dec 20, 2021 04:52 PM Evofem Biosciences (EVFM) CEO Buys 135,000 Shares

Dec 9, 2021 08:03 AM Evofem Biosciences (EVFM) Expects Record High Phexxi Prescriptions, Strong Revenues Growth in Q4

Nov 30, 2021 08:01 AM Evofem Biosciences (EVFM) Announces Successful Type C Meeting with FDA for STI Prevention Product Candidate

Nov 22, 2021 06:50 AM Evofem Biosciences (EVFM) Extends Cumulative Net Sales Covenant Timing to June 30, 2023

Nov 16, 2021 09:41 AM Evofem Biosciences Inc (EVFM) PT Lowered to $2 at Piper Sandler

Nov 16, 2021 06:41 AM Evofem Biosciences Inc (EVFM) PT Lowered to $2 at H.C. Wainwright